LITH IS A TRIPLE THREAT WITH LITHIUM, MARIJUANA & BLOCKCHAIN AND THEIR OWN COIN ON THE AGENDA
Kaboom Coin provides the underserved legal marijuana industry with decentralized banking infrastructure, blockchain based consumer databasing and a payment solution.
LITH is a company operating in 3 hot sectors right now.
They operate in 3 disruptive industries/technologies:
Lithium – with the rise of battery operated vehicles and Tesla’s Gigafactory (as well as other skyrocketing needs or Lithium across numerous industries like energy storage), the current Lithium supply falls far short of the upcoming demand and we’re seeing a “battery miner” boon for Lithium companies.
MJ – Experts say the the MJ industry is heading to $24 Billion by 2025. An increase in support and with additional states passing MJ, the industry is exploding right now… and we’re seeing MJ stocks skyrocket again.
Cryptocurrency – The Cryptocurrency Market Cap Can Exceed $200 Billion by the End of 2017!
LITH is the only company we’re aware of with operations in ALL THREE of these world-changing industries!
“US Lithium Corp. announces it has entered into a Letter Of Intent to purchase blockchain based technology assets from Czech Republic software developer Bank Call s.r.o. Under the terms of the agreement LITH will acquire the website kaboomcoin.com, various registered European trademarks and all of the IP associated with kaboomcoin’s cryptocurrency wallet.”
The news goes on to explain:
“Kaboomcoin.com is an Etherium based cryptocurrency wallet that caters to the 18-35 demographic and the products they purchase whether virtual or brick and mortar.”
“US Lithium Corp. (LITH), announces that it will be pursuing the lucrative legal (MJ) payment market in locations that allow the sale to consumers for both medical and recreational use.”
The news goes on to explain:
“Kaboom Coin (kaboomcoin.com) provides the underserved legal marijuana industry with decentralized banking infrastructure, blockchain based consumer databasing and a paymentsolution. Using Kaboom Coin, industry members will realize significant cost savings as well as assistance with their compliance to state laws. What makes Kaboom Coin different from others in the sector is that we are not solely focusing on cannabis where there may still be some social stigmas associated with the use of something branded specifically for that industry."
"Cannabis is just one vertical that the currency will be aimed at. Kaboom Coin is creating a lifestyle brand around its coin via social media and marketing affiliations.”
It just doesn’t get much bigger than that!
Market Outlook For These 3 Exploding Industries:
Lithium Outlook:
Demand for the metal is forecast to triple by 2025, and according to consultancy CRU, prices for lithium carbonate, used in lithium-ion battery cathodes, have more than doubled since 2015
Benchmark Mineral Intelligence Managing Director Simon Moores stated, “It is our expectation that the lithium industry will struggle to keep up with demand between now and 2021. [We don’t expect an] oversupply [in the market]”
Cost of a lithium battery has halved over the last three years, making electric vehicles cheaper for consumers
If you’ve been paying attention to lithium over the past few months you’ll know why the forecast is so bright, if you haven’t, check out these developments that support the belief that lithium will continue to climb.
Chinese electric vehicle production driven by the recently announced NEV credit system (new energy vehicles) will continue to drive medium-term lithium and cobalt demand; NEV credit scheme encourages Chinese auto manufacturers to improve the fuel efficiency of internal combustion cars and promote the production of electric vehicles.
Europe and India are also forecast to increase their annual EV sales, showing that growth in the electric car space is accelerating faster than expected
Ford said it would reduce spending on internal combustion engines by a third, as it introduces 13 new electric and hybrid models in the next five years
General Motors promised at least 20 new electric models by 2023
In January, when the California Legislature reconvenes, Assemblyman Phil Ting, D-San Francisco, plans to introduce a bil l that would ban new vehicles that run on gasoline or diesel after 2040
Scott Hall, director of communications for the Alliance of Automobile Manufacturers, said in a statement that anufacturers “remain committed to more reductions in fuel use and greenhouse gas emissions, and that’s one reason why automakers are investing billions of dollars in advanced technologies, including electric vehicles.”
MJ Outlook:
New report from New Frontier Data projects that by 2020 the legal cannabis market will create more than a quarter of a million jobs
Currently there are 25 states with some form of legalized medical marijuana and seven states that have legalized recreational marijuana laws that are in various stages of being implemented
Projected total market sales to exceed $24 billion by 2025, and the possibility of almost 300,000 jobs by 2020
Cryptocurrency Outlook:
The total market capitalization (market cap) of cryptocurrencies continues to grow, recently surpassing $170 billion and hitting a fresh, record high.
Figure represents a more than 850% increase from their value of $17.7 billion at the start of this year
Companies raised close to $1.3 billion through Initial Coin Offerings (ICOs) during the first half of this year
Currently, there are more than 50 hedge funds that focus on these currencies
To recap, LITH operates in 3 of perhaps the world’s hottest industries:
Lithium
MJ
Cryptocurrencies
Which is a breathtaking anomaly for a small market company to have its hands in all 3 of these world-changing business, but that’s not the only reason we have our eyes on LITH tonight…
As we stated at the start, we’ve focused on LITH before…… and watched it run 567%!
LITH has been in the high .03s to low .04s for much of the past month, building a base.
This is similar to where it was at a couple of months ago before it popped and rocketed to .06!
– A return to .06 could represent a percentage gain of 38%!
After spending a significant time at this level, LITH could be in a position to make another big move… and considering recent news the sky could be the limit!
At just .037 there could be a very large upside. It has a 52-week high of .08!
A return to .08 could translate to a gain of 116%!
As we said at the start, this play is something quite special.
US Lithium Corp. Signs LOI To Acquire European Developed Blockchain based Cryptocurrency Assets
HENDERSON, Nev., Aug. 22, 2017 (GLOBE NEWSWIRE) — US Lithium Corp. (OTC QB: LITH), announces it has entered into a Letter Of Intent to purchase blockchain based technology assets from Czech Republic software developer Bank Call s.r.o. Under the terms of the agreement LITHwill acquire the website kaboomcoin.com, various registered European trademarks and all of the IP associated with kaboomcoin’s cryptocurrency wallet. LITH will be paying $100,000 in cash and 4,500,000 shares of LITH for the assets.
Kaboomcoin.com is an Etherium based cryptocurrency wallet that caters to the 18-35 demographic and the products they purchase, be them virtual or brick and mortar. This is the most technologically oriented generation in history and the majority of their purchases, communications, social media and payment platforms are tied to their smartphones. LITH believes that this age demographic will more than likely be influenced and adapt to an application and payment method i.e. kaboomcoin, due to their peer circle and social media feeds adopting the product. LITH will be placing resources into the marketing and social media diaspora with kaboomcoin.com.
According to http://www.techcrunch.com/ companies such as Coinbase has facilitated almost $15B in digital currency exchange in just the first half of 2017, which is 5x more that was exchanged in the entirety of 2016. At this pace the startup may see a 10x increase in transaction volume from full-year 2016 to full-year 2017. REF: (https://techcrunch.com/2017/08/10/coinbase-raises-100m-at-a-1-6b-valuation-amid-explosive-growth/)LITH is looking at localizing the digital currency experience for the US and the purchasers of and will have product offerings out for 2017 catering to the unique each state and its set of purchasing rules and regulations.
LITH sees high growth in crypto currencies especially given that the Japanese government formally recognized the cryptocurrency in April 2017, giving it greater legitimacy in Asia’s richest major economy. There’s been steady growth of international money-transfer services that use Bitcoin to move cash from one country to another. LITH views vertical integration is a necessity and a natural progression of the sector.
“We are very excited to be entering and have found and purchased an asset to create a comprehensive and sustainable business model that focuses on enhancing joint company value and shareholder value. We strongly believe that we can develop and finalize an agreement that will profit all stakeholders,” stated Gregory Rotelli, President of US Lithium Corp.
iWeedz.com search engine will be a cannabis information resource that connects consumers with vendors or likeminded individuals. iWeedz will streamline the process of finding the right strains and products for your ailments comfortably, fast and simply. Whether you’re new to cannabis, a medical marijuana patient, or simply a recreational consumer, iWeedz is the perfect destination for you!
iW eedz.com for vendors will be a cloud based solution to manage inventory, post daily deals,attract new customer with proximity marketing via mobile phones, engage with customers viaemai l & text messaging and offer payment processing.
About U.S. Lithium Corporation
U.S. Lithium Corporation is an exploration and development company focused in North America on lithium and related resources for the rapidly growing energy storage industry. The Company looks to capitalize on opportunities within the lithium sector including providing lithium to the ever expanding next generation battery market. Lithium demand is projected to triple by the year 2025 according to a recent report by Goldman Sachs and for many analysts is considered the new gasoline of the future. As the demand for lithium expands, U.S. Lithium Corp intends to be an integral part of this next booming industry. Our current focus is in the Basin and Range province of Nevada where the only producing lithium brine mine in North America, Albemarle’s Silver Peak Project, is located. Elon, our first project, is located in Clayton Valley and is in close proximity to Silver Peak and several other active explorers and developers.
LITHIUM CLAIMS
ELON claims in Clayton Valley, Nevada
The ELON claim block consists of four 20-acre placer claims and is located in Esmerelda County, Nevada, and is contiguous to claims held by both PURE Energy and Lithium X in Clayton Valley. Clayton Valley is home to Albemarle’s Silver Peak Lithium Mine, the only mine producing lithium from brine in North America. Both PURE Energy and Lithium X are actively exploring their respective claim blocks in Clayton Valley.
The Clayton Valley area has been the focus of significant levels of exploration and acreage acquisition in recent months and is considered to be one of the best places for lithium exploration in North America.
Gochagar Lake Ni/Co/Cu Project
The Gochagar Lake property has grades of up to 3.92% Nickel, 0.70% Copper and 2.86% Cobalt as reported by the Saskatchewan government (Mineral Property # 0880). Historical resource estimates (non-NI43-101 compliant) were generated in 1968 and 1990. The 1968 resource for the Gochagar deposit calculated 4.3 million tons grading 0.30% Ni and 0.08% Cu. J.S. Steel, reported in 1990, that vertical and longitudinal sections were constructed from the existing data and an orebody with reasonably well defined limits was defined containing 1,770,000 tones at 0.735 nickel-equivalent.
The Company is undertaking a complete digital compilation, reprocessing and reinterpretation of all available data in and around the Gochagar Lake area. It is utilizing all of the latest available technology and one of the world’s leading massive sulphide experts to bring the project up to modern standards. This phase of the project is expected to be completed in 4 to 8 weeks with an initial NI 43-101 report and proposed drill program to follow shortly thereafter.
Start your research on LITH right away and enjoy.
Sincerely,
AST
Disclaimer: We have received ten thsnd dlrs via a bank wire for the awareness of LITH. We have previously received a total sum of seventy five thsnd dlrs via a bank wire for the awareness of LITH which has since expired.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this report. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
This Tiny Digital Company Is Using Blockchain In A Revolutionary Way
Blockchain technology is disrupting nearly every industry, changing them for the better. If you have been following the news at all, you’ve probably heard of bitcoin and how it is challenging the global payment system. Well, blockchain technology could be applied nearly anywhere. Now, one space that needs a change is the loyal rewards and social influence.
Research studies tell us that loyal customers buy more stuff, provide solid-feedback, refer their friends and family, and often act as brand ambassadors.
However, it’s expensive for businesses to advertise and administrate loyalty programs. Chances are, if you’re subscribed to a loyalty rewards program, you must use your “points” or “dollars” at specific stores and some items might be restricted.
These type of restrictions take the power away from the consumer and companies, making it difficult for firms to keep consumers coming back. Companies are always looking for scalability and exponential growth, but are currently facing a multitude of roadblocks to attract and keep customers.
The solution: Create a global platform using the latest advancements in blockchain technology. In return, creating a seamless alternative for loyalty programs, redemptions and returns.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is trying to do just that…
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC)
FanLogic is not only utilizing blockchain technology to drive the next evolution in brand awareness and consumer loyalty, the company is also using tokenization.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is a Canadian-based digital promotions software company and creator of the FanLogic Connect platform. FanLogic Connect provides agencies and brands with the ability to create striking social campaigns through its innovative gamification techniques.
FanLogic Connect allows its clients to monetize their social media following, while growing their existing audience. The platform draws revenues by collecting a licensing fee. Just one of many streams of revenue for FanLogic, which could contribute to increased share value as more investors catch on.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is leveraging blockchain and tokenization.
The firm is quietly positioning itself to become a market leader. Shareholders of the stock may be rewarded sooner than expected.
Quite simply, blockchain is a shared ledger technology, allowing companies to encrypt, or protect, data on anything ranging from money to loyalty rewards. Blockchain is incorruptible and has no single point of failure, making it highly robust.
Here’s how the technology works:
According to Netscribes Inc, the global blockchain technology market is expected to grow at a compound annual growth rate of 42.8%, reaching nearly $14B by 2022.
According to Research and Markets, “Increasing adoption of Blockchain-as-a-Service, rising cryptocurrency market cap and ICO, simplifying business processes, and creating transparency and immutability are expected to propel the growth of the blockchain market”
That said, FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is revolutionizing brand awareness and loyalty rewards, and only needs a small piece of the market to experience a rise in its revenue and market value.
With blockchain technology, there comes tokenization
Tokenization is an inherent part of blockchain technology. Every blockchain platform is powered by coins, or tokens. Tokens are highly useful for platform identification and accessibility. Tokenization is highly effective when it comes to data security and helps to protect sensitive information, a problem users and companies have had to deal with in the past with large scale data breaches.
The power of tokenization According to Research and Markets, the global tokenization is expected to grow at an immense compound annual growth rate of 22.4% between 2017 and 2022.
Now, FanLogic is planning to use a loyalty token in order to track and reward users’ actions. The loyalty blockchain would be funded from a percentage of fees, which brands pay FanLogic for customer engagement and acquisition. These tokens would be redeemable with all brands in FanLogic’s network. Moreover, it could be used as a currency on its future online gaming site with the opportunity to increase rewards for higher redemption.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is making moves to create a cutting-edge platform for the advertising ecosystem.
FanLogic Interactive confirmed the creation of a stand-alone subsidiary Fanblock.io. Fanblock.io aims to develop, source and adapt new blockchain technology related to any composite part of the brand and celebrity advertising ecosystem, specifically in the loyal rewards and social segment. This is a monumental attraction to the company’s existing clients, as well as large multinational brands due to their existing loyalty programs, which have proven to be expensive and problematic.
FanLogic’s solution to the problems in the traditional marketing and advertising space is to potentially eliminate big brands’ liability through FanBlock.io. The ultimate goal with this subsidiary is to convert the liability to ROI for brands.
Now, FanLogic would use tokens to offer rewards and allow users to trade goods, spend tokens to play games on the network or buy items. FanLogic’s existing programs have been developed to easily adapt to blockchain technology.
According to FanLogic, “Our multi-level platforms are driven through our proprietary peer to peer referral based contests, loyalty programs and incentives, coupons, sweepstakes, charitable initiatives, branded games, 50/50 lotteries and charity draws, and social daily fantasy sports and entertainment contests.”
That said, FanLogic’s platform combined with blockchain technology and tokenization is poised to create a more streamlined approach to social influence and loyalty.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is tapping into the multi-billion dollar cannabis market, further increasing its growth potential.
The cannabis industry is set to grow at jaw-dropping levels, and in the U.S. alone, it’s expected to exceed $40B by 2019. Here’s some projected figures:
Source: Americann
FanLogic recently announced its execution of a Letter of Intent (LOI) with Belgravia Capital International to develop the world’s first unified cannabis automated industry loyalty rewards program. This would further drive the company’s growth, and the revenue model would include set up fees, generation of commissions on tracked and smart-contracted incremental customer purchases.
This innovation is just what the cannabis industry needed.
According to Fanlogic CEO Randy Brownell, “Blockchain is a solution that if utilized properly, allows for the modernization and monetization of traditional and disruptive business lines. Loyalty is our principal focus for deployment of Blockchain, and with the relationship with a leading edge company like Belgravia, we have the opportunity to be a first mover in this loyalty segment. I am thrilled to begin developing this partnership with Belgravia and to explore delivering loyalty and branding to the international legal cannabis industry.”
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) Generates Leads, Marketing and Audience Insights to drive revenues and earnings
Lead generation is one of the primary problems affecting companies trying to attain exponential growth. Through FanLogic Connect, companies would be able to drive revenue and cut costs, while boosting profitability. FanLogic would drive direct sales through the use of contests to boost the bottom line. Consequently, this would outstandingly improve ROI for marketing, compared to traditional techniques.
FanLogic’s real-time contest reporting empowers clients and provides accessibility to specific daily contest information to summarize key metrics influencing the success of contests.
The metrics include:
“Automated data collection at every point of the contest entry process
Real-time, contest specific data to effectively manage campaigns, client reporting and measure effectiveness
Lists of registered participants at the completion of a campaign
Aggregation of registered participants to a central database for selective remarketing usage
“Hooks” allow for secondary revenue streams (ads in registration pages, text links in follow up emails) Integration into existing personal relationship networks such as Facebook, LinkedIn, Twitter, etc. to enable those networks to spread our clients’ messages faster and more effectively”
Source: FanLogic
Another problem with the traditional advertising industry is using data to find the right target audience. FanLogic Connect collects a wealth of data from contests including:
Buying habits
Income
Circle of friends
Interests
Education level
Location
Status
Age of friends and relatives
Rather than targeting advertisements with the data, FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) takes a unique approach by targeting contests. FanLogic is looking for users who would be motivated to enter contests to win various prices ranging from cars to tickets to a show or sports event. Using deep data, FanLogic allows companies to figure out how to target their campaigns to the right consumers.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) has multiple revenue streams and could benefit from various industries such as: sports and entertainment, gaming, substantial brands and products, cannabis, ad agencies, and hospitality, travel and tourism.
With the innovative and ingenious creation of FanLogic Connect, could attract new clients, potentially increasing its revenues and earnings, which are generally key drivers of market capitalization growth.
Blockchain, Tokenization, Marketing and Loyalty Rewards Companies Have Been Hot.
Some blockchain related stocks have been skyrocketing, most notably Overstock.com (NASDAQ: OSTK), which had a bullish run up after it announced it would be implementing tokenization.
In under one month, OSTK moved up over 70% off of the tokenization news.
Hubspot Inc (NYSE: HUBS), which is in the same space as FanLogic, ended 2017 up over 80%, and ran up nearly 30% in December 2017 alone.
Additonally, RetailMeNot was acquired for over $600M, over a 50% premium to its closing price when the deal was announced, in 2017.
If FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is able to execute and create its modern FanBlock.io platform, this could be the next stock in the blockchain, tokenization and advertising space to catch the markets’ eye.
The Bottom Line
The demand for blockchain and tokenization is abnormally high, and many companies are trying to get into the space and leverage the power of the technology. When applied to the advertising and marketing space, blockchain and tokenization has positive implications, potentially allowing companies to better target their campaigns.
FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is one of the leaders in the digital promotions software space looking to implement blockchain technology and tokenization. Blockchain-related stocks, like Overstock, and marketing stocks, such as Hubspot, have had strong performances, and FNNGF could runup with its breakthrough platform.
Disclaimer: We have not received any form of compensation for the awareness of FNNGF.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this report. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
STOCKTA HAS THIS ONE “BULLISH” WHILE BARCHART HAS THE CANADIAN SIDE A “STRONG BUY”!!!!
Assets grew over 75% in just 3 months!
Our last play worked out well. It bounced back and was up 27% today and is still sitting nicely above the alert price. It looks as though all the selling has gone away on that one and we expect it to move higher on any buying pressure.
Remember that we also gave you a MJ play back in October that just hit highs a few days ago that showed us 50%+.
There are a few hot industries out there right now. If you could pick 5 that really stand out, Lithium would most definitely be in that conversation.
According to a report released today by Zion Market Research, the global lithium-ion battery market was about $31.1Bln in 2016 and is expected to reach $67.7Bln in 2022. More on lithium in a moment… first, a glance at tonight’s lithium play that already has Phase 1 & Phase 2 Drilling Program results.
What happened to our last lithium/cobalt play?
That is correct, it shot up way above level even traders thought would be the top resistance points.
Note: The StockTA analysis pictured and linked above is for Far Resources’ OTC symbol FRRSF. Because FRRSF is new to the OTC Barchart does not have an opinion yet, so the Barchart link above is for Far’s CSE symbol, FAT.
As you can see, it’s about as perfect as it gets – StockTA doesn’t even list Resistance, only support… and FRRSF is a heck of a lot more than just a pretty chart. According to their latest CSE filing (numbers in CDN):
– As of June 30th, Assets Total: $2,795,874
– In March of 2017 Assets Totaled: $1,586,415
That’s more than 76% growth in FRRSF’s Assets in just 3 months!
Lithium, an essential component in modern car batteries and battery-operated cars, is the future of transportation:
– China wants 5Mln electric cars on the road by 2020
– California plans to have 1.5 million “zero-emission vehicles” by 2025
– California lawmakers want to “ban the sale of new cars fueled by internal-combustion engines after 2040”
– Goldman-Sachs called lithium the “new gasoline”
$67.7Bln is a monster number that shows us the evidence of the current “Lithium Boom,” but it doesn’t tell us the whole story. You see, until very recently, lithium was mined by just 3 companies… 3 Very Big Companies… yet as large as they are, they’re not capable of mining the massive amounts of lithium needed to meet the skyrocketing demand.
This massive gap in supply vs demand – potentially a $30BLN gap – is being filled by small mining companies new to the lithium game; and any time a Small company finds itself in a Big situation… well, that pretty much exemplifies the companies we search for.
One of these companies, Far Resources Ltd (OTCMKTS: FRRSF)(CSE: FAT), is a bit ahead of the field in its lithium mining & assay efforts and has recently built a near-perfect chart that just can’t be ignored:
In mining it’s not always what you have but where you have it, in many cases the location of your exploration will determine the viability of your operations. In the case of Far Resources Ltd. the location of their two options couldn’t be better situated.
According to the Fraser Institute, Manitoba- home to FRRSF’s Zoro Lithium Property, is ranked as the world’s second best jurisdiction for mining investment.
Additionally, the company’s second option is the Winston Property, a silver and gold property located in New Mexico, USA, which is also ranked in the top 25 mining jurisdictions in the world by the Fraser Institute.
We’ll look at the lithium property first, but keep this in mind:
According to a report by Zion Market Research, the global lithium-ion (Li-ion) battery market was valued at around USD 31.17 billion in 2016 and is expected to generate revenue of USD 67.70 billion by end of 2022 and growing at a CAGR of slightly above 13.70% over the forecast period.
Metals and minerals consultancy Roskill Information Services provides a base scenario for lithium consumption at 290,000 tons in 2020. However, that figure rises to a sizeably larger 420,000 tons in what it calls its “optimistic” scenario.
Situated in west-central Manitoba within the historic Snow Lake mining camp, the Zoro1 Claim covers a significant lithium pegmatite occurrence known as the “Principal Dyke”, it contains an historic “reserve” based on 1956 drilling of 1.8 million tonnes grading 1.4% Li2O to a depth of 305 m.
Recent news surrounding Zoro Lithium Property:
Entered into an MOU with Quantum Resources Limited, an exploration company that has the right to earn an interest in the Thompson Brothers lithium project which is contiguous with Far Resource’s option
As part of MOU. Both companies have agreed to exchange information and to work together to assess the viability and potential synergies of developing their lithium assets in Manitoba together over the course of a one-year period
During the period of the MOU, the parties will explore the most efficacious way to work together to move their projects forward through a mutually beneficial agreement to both parties
Addressing this MOU, Keith Anderson, President and CEO of Far Resources, summed up the significance of the deal, stating, “I am excited about the potential that can be unlocked by working together with Quantum on our lithium projects in Manitoba. The MOU represents the possibility for operational synergies and development options that will benefit Far Resources and our shareholders. We will be actively proceeding to investigate these possibilities to the mutual benefit of all stakeholders.”
Assay Results Released November 27, 2017:
Company prospectors collected 60 representative rock chip samples from historic trenches and pits in Dykes 2, 3 and 4. These samples were analyzed for multiple elements including lithium and related metals
High grade lithium with maximum values of 1.42% and 2.71% Lithium Oxide (Li20) were documented from Dykes 2 and 4 respectively
Results increase the number of known high grade lithium-bearing pegmatite dykes on the Zoro property thereby providing targets for upcoming diamond drilling
Commenting on the results, Anderson stated, “The number of significant lithium-bearing pegmatite dykes on the Zoro property continues to grow as our geoscientific data becomes available. Two prospecting teams are now on our newly acquired ground at Zoro to explore for new lithium-bearing pegmatite. We also anxiously await assay results from our recently completed drill program on Dyke 1.”
Now for the gold and silver option in New Mexico. Once more something to keep in mind:
TD Securities commodity analysts have expressed a bullish position for both gold and silver in their 2018 Global Outlook- saying “its trade recommendation for next year is to go long silver” while also expressing optimism for a steady climb in gold prices.
Famed investor Jim Rickards has stated he is not convinced the Fed will raise rates next month at its monetary policy meeting and if they don’t he maintains that gold prices could reach $10,000 an ounce.
Winston Property
Located in Sierra County, New Mexico the property includes the Little Granite Mine as well as the Ivanhoe-Emporia Mines
Little Granite Mine– a high grade, past-producing underground silver-gold mine located in the Black Range Mining District of New Mexico. The main structure hosts a low sulphidation epithermal quartz vein (similar to the high grade Midas and Sleeper mines in Nevada), which has been traced for over 500 feet by underground workings and exploration drilling
Exploration Plan
Phase 1 – $350,000
– Diamond Drilling, to verify historic drilling results
– Property Maintenance
– Improved Road Access
– Field Sampling
Phase 2 – $600,000
– Ground Geophysics
– Data Analysis, Research
– Geo Re-Interpretation
– Diamond Drilling
Ivanhoe-Emporia Mines– mines are past producers of gold and silver, with a decline of 370 feet. They have potential for a large tonnage of lower grade, stockwork veins surrounding high-grade veins mined in the past
Project overview:
– Past producing gold-silver mine
– Main shaft to 384 feed depth
– 370ft decline
– Potential for large tonnage of lower grade, stock work veins surrounding high grade veins mined in the past
– Soil geochemistry and geophysical anomalies defined for follow-up when funds available.
Conclusion:
In the last three to four years we’ve personally spent more time researching lithium than any other industry. In an era of disruptive technologies and advancements, lithium is disrupting the automobile industry.
Take a moment to think about that – one of the world’s largest industries that has generated trillions over more than a century and created household name icons is being turned on its head!
And amongst the biggest winners of this “electric car revolution” is lithium.
So, to recap, here is the blockbuster we’re looking at tonight:
– FRRSF operates in one of the world’s hottest industry
– FRRSF’s chart is drop-dead gorgeous
– FRRSF already has quality drill results that are generating A LOT of attention
– FRRSF has started to move, closing today at $0.7686
– FRRSF has major assets on its books
– Volume is building – over 537K today
FRRSF closed today at $0.7686, just off the day’s high of $0.8061 – there could be more room to run tomorrow!
If you didn’t click on the Barchart link at the top, this is what you missed:
That is a lot of green; how much further can FRRSF continue on this epic run?
We’re looking at a ground floor situation that is already exploding.
Make sure you put FRRSF & FAT.CN are the top of your screen right away.
FRRSF closed at $0.7686 today.
Far Resources Canadian issue, CSE:FAT, closed today at $0.86 with 6,013,000 in volume – nearly 3 times its daily average.
Sincerely,
AST
Disclaimer:
We have received fifteen thsnd dlrs via a bank wire for the awereness of FRRSF. All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
Let’s face it, the injection experience for some doctors and patients is outdated, and the traditional syringe has been unchanged for nearly 160 years.
Even with improvements in the healthcare industry, hypodermic syringes have stayed the same.
Now, Milestone Scientific Inc.(NASDAQ:MLSS) is looking to change the game and committed to advancing the science of computer-controlled drug delivery system, offering efficiency and patient comfort gains for both the medical and dentistry fields.
Milestone Scientific (NASDAQ: MLSS) Company Profile
Milestone Scientific is a leading medical research and development (R&D) company that’s designing and patenting innovative injection technology. With Milestone’s innovative computer-controlled systems, medical and dentistry professionals are able to make efficient, precise and virtually painless injections, and could take a large portion of the traditional injections market share.
MLSS offers its revolutionary DPS Dynamic Pressure Sensing Technology, which aims to meet the needs of various subcutaneous, or under-the-skin, drug delivery injections and fluid aspiration. This groundbreaking technology enables healthcare professionals to attain a plethora of unique benefits, which cannot currently be accomplished with the traditional manual syringe. This technology is Mileston Scientific’s patented system that has been used in over 65M dental injections.
The DPS Dynamic Pressure Sensing Technology has innovative features, allowing medical professionals to: measure tissue density to identify the exact needle location, control the flow rate of fluid, and provide precise tactile control. In turn, patients are able to receive injections and fluid aspiration with less pain.
Milestone Scientific’s technology empowers clinicians to receive real-time continuous feedback as to the local tissue conditions during the injection process. With the real-time feedback, healthcare professionals are able to accurately differentiate and identify specific tissue types and anatomical locations, making subcutaneous drug delivery safer, more effective and easier, transforming the traditional injection market.
Milestone Scientific’s Product Line
Milestone Scientific currently has three featured products: The Wand, CompuFlo Epidural and CompuFlo Intra-Articular.
The Wand is a computer-assisted system for local anesthesia. The Wand is the market leader in injection technology, and it’s the first of its kind and the best in its class. That in mind, MLSS has first mover advantage in the space, and differentiates itself from companies offering traditional local anesthesia injections.
The benefits of The Wand Computer Assisted Anesthesia System include: patient satisfaction, a new marketing opportunity, less stress and more options and flexibility for dentists, and increased productivity due to its rapid onset. When dentists use this technology, patients are more comfortable and less anxious, and The Wand could eliminate collateral numbness, allowing patients to get on with their day without a numb face.
Dentists are already implementing this technology, and there are hundreds of dentists across the U.S. As more doctors adopt Milestone Scientific’s The Wand product, the company should generate higher revenues and earnings, which should boost the company’s stock price.
Milestone Scientific (NASDAQ:MLSS) also offers CompuFlo Epidural, a safe and effective way to administer epidurals using pressure-sensing technology, offering a multitude of benefits for both medical professionals and patients.
Medical professionals, specifically anesthesiologists, are able to use both hands to advance and direct the needle, as well as objectively confirm, in real time, the epidural space with 99% success on the first attempt.
Unlike traditional epidural injections, there’s a lower likelihood that doctors need to reposition needle over multiple attempts, benefitting patients. Moreover, CompuFlo Epidural offers the potential for a radiation-free solution for identifying the epidural space in pain management patients.
CompuFlo Epidural leverages Milestone Scientific’s patented DPS Dynamic Pressure Sensing Technology, which helps to differentiate tissue types for medical professionals via audio and visual feedback. Consequently, this leads to precise location guidance as the needle advances toward the intended injection area. This helps to reduce the number of required attempts to accurately identify the epidural space, potentially making the patient’s experience less painful.
MLSS announced in June 2017 that CompuFlo Epidural Computer Controlled Anesthesia System received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Based on both nonclinical and clinical tests that were conducted, Milestone Scientific demonstrated CompuFlo Epidural device’s safety, efficacy and performance, in relation to other legally marketed predicate devices.
According to former Milestone Scientific CEO Leonard Osser, “Looking ahead, we are now focused on reaching out to the top KOLs in the U.S., as we have been doing successfully across Europe. The CompuFlo® Epidural System’s ease of use allows use by medical professionals with varying levels of experience, which further drives the value proposition of this technology. In addition, due to what we see as the device’s add-on value proposition, we plan to seek reimbursement codes over and above those already in place for traditional epidural procedures.”
Not only that, but MLSS recently announced that its CompuFlo Epidural System was successfully utilized in over 500 epidural procedures, including pain management, and labor and delivery. The CompuFlo Epidural System has been implemented in various settings at multiple leading institutions in Europe, South America, and the U.S.
MLSS Chairman and Interim CEO Leslie Bernhard stated, “Following our recent 510(k) clearance from the U.S. Food and Drug Administration, I am pleased to report we are successfully executing our strategy of placing the CompuFlo® Epidural System with key opinion leaders in the U.S., Europe and around the world. To date, we have successfully completed over 500 procedures with zero complications. These results are particularly significant considering the potential risk factors associated with a traditional epidural procedure.”
Milestone Scientific’s CompuFlo Intra-Articular Instrument allows medical professionals to administer accurate joint injections, without the risk of radiation. Although the CompuFlo Intra-Articular Instrument is not available in the U.S. yet, the company could file for FDA approval in the U.S., and if it’s able to receive approval for this product, MLSS could see further growth in its revenue and earnings, potentially driving the stock higher.
Now, there are numerous benefits for medical professionals and patients. The CompuFlo Intra-Articular Instrument provide medical professionals with:
Precise computerized injection and drug delivery accuracy
Needle deflection prevention
Portable, reliable, versatile technology
Lightweight and easy to use with two power sources, a standard AC plug, as well as a built-in lithium-ion battery pack
1 USB 2.0 port located on the rear off the instrument for allowing transfer of patient files in a .csv format for permanent storage
Additionally, CompuFlo Intra-Articular is designed to regulate the flow of fluid in order to reduce patient discomfort.
Milestone Scientific Could Tap into the Billion Dollar Syringe Market
There are a plethora of markets that Milestone Scientific could take a large portion of. According to Grand View Research, the global disposable syringes market size was valued at $6.4B in 2015, and this market is expected to grow due to the increasing demand for injectable drugs. By 2024, the global disposable syringes market is expected to reach $9.9B.
Additionally, according to Markets and Markets Research the prefilled syringes market is expected to reach $6.36B by 2021, from $3.93B in 2016, or a compound annual growth rate of 10.1% for the forecast period.
Not only that, but Grand View Market Research also projects the U.S. smart syringes market to grow to more than $3B by 2024, from just over $1.5B in 2015.
Milestone Scientific’s Competitors Are Thriving, and They Could Look to Acquire MLSS
Baxter International (BAX) is one of Milestone Scientific’s competitors, and it could look to acquire MLSS.
BAX has seen a strong rise in its stock price since the beginning of 2017, growing nearly 30% year to date.
Illumina Inc. (ILMN), another competitor of MLSS, has also seen some strength, rising over 55% year to date.
As more healthcare professionals shift towards Milestone Scientific’s products, MLSS could take a large chunk of the market share from its competitors. Additionally, this makes MLSS a potential acquisition target for large healthcare companies, due to its innovative and highly beneficial products.
With MLSS competitors growing significantly in market value, they could look to acquire MLSS for its technology, rather than conducting R&D and spending billions of dollars to try to develop technology similar to that of MLSS.
Final Thoughts
Milestone Scientific has over 20 patents, and its changing the way healthcare professionals provide injections to patients. With The Wand, CompuFlo Epidural and CompuFlo Intra-Articular, MLSS is well positioned to take market share from its competitors, in the injections and syringes markets.
With MLSS receiving 510(k) FDA clearance for CompuFlo Epidural Instrument, as well as the company’s announcement of more than 500 successful procedures using the system, competitors and investors might start taking notice of the growth potential in Milestone Scientific. Additionally, the patented DPS Dynamic Pressure Sensing Technology has been used in 65M dental injections, and once more dentists and doctors adopt this system, there should be a strong rise in MLSS sales and earnings, which are some of key drivers of the stock.
MLSS has a compelling story and is innovating the way medical professionals conduct injections, and it seems like it’s one catalyst away from a large move, to the upside. Investors and traders who want exposure to the micro-cap healthcare market may want to consider MLSS due to its growing presence in the traditional injections market.
We have received five thsnd dlrs via a bank wire for the awereness of MLSS. All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
I have to say it was a small shock to me that the major brands in the food sector have not focused their attention on night time snacking. Yes there are a few semi healthy options, but nothing in comparison in taste and satisfaction as day time ones provide.
Or, perhaps the big players are waiting for a small cap to create the market, achieve proof of concept which kicks off talks of a buy out or licensing, its a cheaper way for the big players to make sure they don't end up walking into a sector that may not work.
Well, NGTF has done a fantastic job of placing its stake in the night time snack industry just as its most needed given the rise of the Medical Marijuana sector; the munchies, a side effect that drives an entire industry……think about it.
Some interesting information I found during my search:
http://www.betterretailing.com/couples-night-in/ – “Evening snacking is a high-value opportunity for retailers – out of all snacking occasions, it’s time together with partners that consumers are willing to pay the most for,” says Rebecca Worthington, Pringles senior brand manager.
Mintel is the worlds largest market research firm and they have identified night snacking to be one of their key food and beverage trends for 2017 and beyond as you can see there. The free report touches on it further.
Bottom line:
1. NGTF is the only company currently addressing one of the key consumer trends of the next decade
2. NGTF recently hit new revenue milestones and expect much growth in coming months
3. M&A is rampant in the snack space at very high multiples of top line revenue and we are the pioneer and creator of a category, it's reasonable for somebody to fathom an even bigger valuation.
Sincerely,
AST
Disclaimer: We have received five thsnd dlrs via a bank wire for the awareness of NGTF. We have previously received twenty thsnd drls via a bank wire for the awareness of NGTF which has since expired.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.An
Any copywriting or redistribution of this article in any shape or form is not allowed without the written concent of the sites owners.
Between 10% to 15% of people in the world suffer from Irritable Bowel Syndrome…….
A number that is continually growing and today's treatments come with unwanted side effects, creating the environment for new developments in what is still considered "unconventional" but could be the future of medicine….
VBIO really does have advancements that could be the "future".
A Little About VBIO:
Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders.
We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as inflammatory bowel disease, narcotic bowel syndrome, and multiple sclerosis.
In our programs, we aim to go beyond merely providing symptomatic relief to patients afflicted with these disorders, and to instead provide targeted therapies that can provide long-term or durable relief, as well as even help them recover lost function.
About Industry:
Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, some prodrugs may be approved rapidly through demonstrating similar bioavailability or bioequivalence.
At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. In our case, targeted delivery could enable oral drug formulations of cannabinoids that provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream.
A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 20 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.
LOS ANGELES, CA–(Marketwired – Aug 2, 2017) – Vitality Biopharma, Inc. ( OTCQB :VBIO ) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1 million private placement.
LOS ANGELES, CA–(Marketwired – Jul 19, 2017) – Vitality Biopharma, Inc. ( OTCQB :VBIO ) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can be targeted and limited to the gastrointestinal tract, thereby avoiding drug psychoactivity and unforeseen side effects. In a preclinical model of inflammatory bowel disease (IBD), cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls. Vitality's cannabosides were successful in treatment of an acute model of colitis (DSS), which is traditionally viewed as very challenging, given that certain FDA-approved therapies including corticosteroids and TNF-alpha inhibitors have been shown to be ineffective for treating this model. The positive preclinical efficacy results with cannabosides are required in order for the Company to progress into first-in-man clinical trials.
The presense of a potential catalyst here is impecable, there is a reason why VBIO is trading over a dollar!
Keep in mind, pharam plays recently have become like the old days of mining companies in the OTC world, no cash, borrowed assets, no reveneus, yet 10 times valutions…...it is unreal.
VBIO has revenues, fully reporting, three star rating and making advancements in the sector of the medical world that does not yet really exist. But that is where those who have the mindset invision the future, and create the science that froms into a new standard in the future.
Please, I urge you to start you research on VBIO right away and enjoy.
Sincerely,
AST
Disclaimer:
We have received seven thsnd dlrs via a bank wire for the awereness of VBIO.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
MOCI On a Path to Disrupt Global Media Production and Distribution
As the third quarter winds down, market participants are beginning to see a move toward a diffusion of capital by larger fund managers. Higher nominal growth in the global economy is sparking a rotation trade out of mega-cap technology stocks like Facebook (FB), Google (GOOGL), and Amazon (AMZN). And rumors of a tax reform bill hitting the wires has fueled a rush of those funds into domestic, high-beta stocks.
That means: small caps and micro-caps are on the move again.
The river of money coming into these market segments will be looking for two things: a good story and an undervalued position relative to a big end market. As far as we can see, MOCI is as attractive as anything out there from that perspective. However, this company is more than just another pretty face value setup: these guys are up to something that could be a unique and valuable innovation a market segment with virtually no pure-play competition.
The game is the coordination and development of a new model of market-based funding mechanisms supporting independent cinematic media that explicitly targets underserved emerging markets. It’s fascinating, and it might be hugely lucrative as well.
Quick Facts:
MOCICEO Ross Cooper is one of the most experienced guys in the industry, with three decades in the game.
MOCIalready owns a successful Chinese film fund and is looking to expand its operational reach and investments in emerging markets worldwide.
MOCIhas begun to crusade for a new process to manage and view mobile video, with an innovative exchange model to network together financing from .
MOCIis an emerging leader in the nearly $80B mobile app space.
MOCIis coming off an RSI trough under 45, pointing to a massively oversold stock now heading back the other way.
MOCIjust recorded a MACD Bullish reversal, suggesting a technical change in trend.
MOCIis knocking on a potential technical breakout that could occur on a surge above the 200-day simple moving average at $0.95. The stock recently broke out above its 50-day SMA earlier this year, and has held those gains.
Understanding the Basic Story
Modern Cinema Group Inc. (OTCMKTS:MOCI)is gearing up, as far as we can see through our research, to disrupt the business of film making. This is a new kind of Hollywood studio. The emphasis is on creating a new model for how movies and television shows are financed as the modern content-sphere becomes an increasingly global phenomenon.
If you set out to make a new film, you may need to go affiliate with a major production house and they will work with you to pitch to investors and fund the production if the project makes business sense.
That’s the way it is currently done, and has been done for a long time.
MOCI is looking to change all of that. That model doesn’t work if you have a project that could really work in the emerging world. The fundraising step is where the operation breaks down. However, MOCI is working on a model that borrows from the mechanisms inherent in the functioning of futures exchanges to distribute the weight of the financing process among self-interested and unconnected speculators.
If the model gets traction, it could truly revolutionize not only how films and TV series are financed, but also the range of projects that can be seen as economically viable in the first place. This last point is critical to fostering a burgeoning media consumer culture in market territories such as Asia, Europe, Africa and South America. But, whoever solves that puzzle could potentially capture and have direct connection to over 50% of the world's population. So this is Big Game stuff.
That brings us to another point of strength: The company’s CEO is Ross Cooper, a man with 30 years of experience as a successful entrepreneur and corporate officer. According to the company’s materials, Mr. Cooper is also an accomplished inventor with numerous patents to his name.
From what we can see, Cooper has been an innovator throughout his career and continues to find avenues that provide an edge. He has a few exits already as an entrepreneur and managed to entrench himself in the fabric of Hollywood as the Executive Producer for movie, television and music projects.
Mr. Cooper has been responsible for the creation and operation of many companies in the areas of Media & Entertainment, Education, Psychometrics and Health Sciences. Mr. Cooper is currently negotiating the rights to his original story named “Wingman”.
Now, he leads this new effort to exploit the virgin territory of emerging market dynamic media content financing and distribution. According to company materials, MOCI has numerous divisions that provide novel and timely solutions with the ultimate goal of building a worldwide dominant motion picture network. Right now, Modern Cinema Group provides libraries of movies, television and game content to large population groups by way of its distribution partners (primarily mobile carriers).
During the summer of 2014, Modern Cinema opened a film (and media) financing fund within the Free-Trade located in Shanghai China before these types of funds were closed to foreign entities.
Since China is now the largest market for filmed entertainment, and media investments in China are highly attractive to the numerous funds; Modern Cinema Group is well positioned to either finance or co-finance productions along with Chinese entities (both private and corporate). Modern Cinema plans to begin Chinese Co-Productions in early 2018.
One of the company’s primary insights is a focus on “pre-positioning” media content, where users are able to gain on-demand access to content actually stored locally on the device. This circumnavigates one of the primary hurdles to consumer experience of media where infrastructural resources are second- or third-tier.
With this in mind, one can imagine that MOCI execs are targeting the 2018 World Cup as a major breakout point for the business: nothing is more core for emerging market media engagement than the World Cup. And this is exactly when mobile carriers will need to increase efficiencies as these games will introduce unprecedented demands on mobile networks in Latin America, Europe and Asia. Modern Cinema Group and its partners are working to secure opportunities for the World Cup now.
A Brave New World
The move to focus on emerging markets is itself enormously compelling precisely because the niche offers a mouth-watering combination of low-competition and high potential growth over time. The only hurdle is the technological barrier to entry: the reason why competition is low is because the economics normally don’t favor targeting media towards emerging markets given that costs of production and distribution may be higher and revenues from things like advertising are normally going to be quite a bit lower. So, the ROI simply isn’t there.
That is true unless you start with a new model for both financing projects and distributing media. That appears to be exactly where the MOCI story is going. With a diversified funding draw model and an ability to drive high-quality locally-relevant media content to consumers operating on older (3G and 4G) mobile networks with major delays or buffering obstacles is the holy grail. And it would appear that Cooper has his team on tract to make a run at this outcome through Multicasting using MBMS. Newer LTE networks will use eMBMS or LTE Broadcasting.
As the company’s materials explain, this allows both older 3G/4G and newer LTE networks to potentially send our content to millions of user devices simultaneously. The content titles will be stored on user’s devices to be played at a later time (On-Demand) — the Pre-Positioning methodology we covered earlier.
According to the company’s website, MOCI Media is already in contract negotiations with mobile carriers located around the world.
Technical Analysis
As it stands, the stock has been increasingly showing signs of a being in a new and burgeoning bullish trend: we saw a clear bullish breakout above its 50-day simple moving average in June on a bullish inflection in the MACD indicator.
Those gains have been preserved, and the stock is now clearly knocking on the door of a similar breakout above its 200-day SMA as well. That could push shares above the key psychological marker at the $1/share level.
All of this has happened ahead of a planned surge in investor relations noted by management as a next step, suggesting that we are sitting in front of a positive technical feedback loop with major implications.
About MOCI
MOCI (Modern Cinema Group Inc.) is a new Hollywood studio “disrupting the way movies and television series are financed in the new Golden Age of Content Everywhere.”
Based in Beverly Hills, founded in San Diego, the company has a decidedly technological spin on how to finance movies by allowing the world's largest Multichannel Video Program Distributors (primarily Cable and Satellite Operators) to compete with on-line services by offering their own branded Hollywood movies and television series. The production budgets for movies being between $40 million and $100 million. Budgets for television series in the range of $100 million per season. Financing partnerships currently in place with numerous Chinese Film funds.
Sincerely,
AST
Disclaimer: We have received five thousand dollars via a bank wire for the awareness of MOCI. All of the information in this blog is gathered from public information released by the company. By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.
Following our enormous win the junior gold mining space earlier this month, we are now ready to turn our attention to another market segment that offers the potential for home runs and grand slams on a regular basis: biotechnology.
Now lets research OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). And, fortunately, it’s not a difficult study: there’s a ton to like here right now, particularly following the company’s most recent announcement detailing its success in its Phase Ia trial for its lead pipeline asset, ProscaVax, which is now heading into a Phase II study with momentum and promise, and toward the $7B prostate cancer market.
But OBMP is not as simple as the ProscaVax story. In recent months, under the leadership of its …., the company has diversified widely with the goal of funding future operations and R&D through actual revenues rather than hopes, promises, and dilution, which is the more common path for early-stage biopharma plays. That’s our focus today: why this company is different.
Quick Facts:
OBMP has a small trading float of just 9.8M shares, which suggests the stock could launch higher on any additional influx of interest.
OBMP has a lead drug candidate heading into the possible commencement of critical Phase 2 trials in the $7B prostate cancer space, with phase one now well sorted out.
OBMP acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH over the Summer. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.
OBMP also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.
OBMP is working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.
OBMP management recently noted that the company had a total of 48 drugs/drug candidates that “are already under our control for specific markets or are the subject of negotiations.”
OBMP is one of the most diversified biopharma microcaps on the OTC today, with an enormous array of revenue paths set to hit over coming quarters.
Understanding the Basic Story
OncBioMune has too often been lumped into the one-horse prostate cancer lotto as a shorthand way to understand the company. And that has misled longer-term shareholders into giving up on the story, which is perhaps the most compelling reason for new investors to take notice and give this stock a fresh appraisal. The critical factor in understanding exactly why that one-horse prostate cancer lotto story is wrong is the company’s process of intense diversification in its top-line potential over the past 6 months. In that time, we have seen one announcement after another that all focus on the same narrative: marketing and distribution rights to therapies that have commercial viability now.
The story really started with the acquisition of Vitel Laboratorios, S.A. de C.V, which got the ball rolling for sales in Mexico of the Company’s licensed products, Bekunis for constipation and Cirkused for stress. They both exceeded projections during the first six months on the market and represented two commercially viable horses in the stable.
Sales from September 16, 2016 to February 16, 2017 were approximately $330K, exceeding projections for $125K initially forecast for the first six months at product launch during the third quarter last year. The Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to $850K for the products in 2017.
But that was just the beginning.
Just after the Vitel move, OBMP execs pulled off another similar move, announcing the signing of a licensing agreement between the Company and PROCAPS S.A.S. granting OncBioMune rights to tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL), throughout Mexico, Central America and Latin America.
That was followed by the company’s announcement of an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH, a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.
OncBioMune and AqVida are currently conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.
Rather remarkably, the blitz toward commerce and revenues did not end there.
The company recently announced that it has formally acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.
In this string of strategic moves, one might easily have overlooked yet another move tucked into the middle of Summer, when the company announced that it is now working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.
Most recently, in an interesting move, the company has also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.
The Revenue Train
Hence, this is far, far more than just an early stage R&D play in the prostate cancer space. This is quite possibly the preeminent rising biopharma play in the Mexican and Latin American markets, with commercially viable revenue streams taking root in markets as diverse as Stress, Constipation, Rabies, AAT, Cancer, and Leukemia.
The moves are already starting to pay off. The company announced sequential top-line Q2 growth of 935%. That type of number should send a flare up to momentum investors if the stock starts to establish some newfound momentum on the chart.
We are coming into the end of Q3, and folks are sure to start to pricing in another major jump in sales. But the real remarkable point might come into year-end, when several of the company’s newest horses start to leave the stable and join the race, such as the six new products it will begin commercializing in Mexico in Q4 as part of its roha partnership deal.
However, perhaps the most interesting story is the mysterious AAT deficiency opportunity recently alluded to in company communications. Management is being a little cagey about the details for competitive reasons, but they are not being coy about its market potential.
“This is absolutely a blue ocean opportunity for us that could generate tens of millions of dollars in high-margin revenue by helping just a small portion of patients with AAT deficiency in Mexico. The first patient’s private insurance has already agreed to reimbursement, a positive sign for us moving forward,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Patients with AAT deficiency need to know that they have the disorder as soon as possible, information that could potentially lower the risk of developing life-threatening diseases by early intervention. We are optimistic that we will successfully negotiate the licensing agreement and fill this area of unmet medical need in Mexico.”
AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually. That’s where the “tens of millions in high-margin revenue” notion comes from.Any way you slice the OBMP story right now, you get further and further away from the typical “one-horse, pre-revenue biotech betting it all on a long-shot.” This is strategically diverse commercial-stage organization with 48 horses in the stable and a radical top-line revenue growth acceleration that has already begun.
ProscaVax
That said, the biggest horse in the stable is still its prostate cancer ticket, ProscaVax.
The drug recently completed a Phase 1-a study with strong results. The study enrolled 20 biochemically progressing prostate cancer patients, four of which dropped out due to disease progression (3 with increasing PSA, 1 radiological).
Perhaps even more interestingly, the study further evaluated secondary objectives that could suggest efficacy for ProscaVax having a meaningful benefit in treating late-stage prostate cancer. According to the company, “At a median follow-up of 31 months post-final vaccination, 9 of the 14 evaluable patients (64.3%) who received all six vaccinations had increased PSA doubling time, suggesting ProscaVax was slowing tumor growth. 12 of 15 patients (80.0%) completing the protocol had an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay.”
That is basically the ideal outcome for a Phase 1 study: no toxicity, but indications of a therapeutic benefit. From here, we will likely now see the company release full details of the plan going forward, including the outline of its upcoming Phase 2 research on the drug.
As noted above, the prostate cancer market is massive, with over $7B in total sales on the line. If the market begins to take ProscaVax seriously – as a real contender in this space – then we could be looking at a massive repricing of OBMP shares. The successful closing of its Phase 1 study puts that on the table going forward.
About OBMP
OBMP (OncBioMune Pharmaceuticals Inc.) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products.The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. The company also has a portfolio of targeted therapies for international marketing and is headquartered in Baton Rouge, Louisiana.
Disclaimer: We have received five thsnd dollars via a bank wire for the awareness of OBMP. We have previously received five thsnd dlrs via a bank wire for the awareness of OBMP which has since expired.
All of the information in this blog is gathered from public information released by the company. By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
2017's Biotech Alert of the Year Is Here! INOL's Inojex30 is the ONLY FDA Approved Device Of It's Kind in a $9.8 Billion Market! With a Shortage of 300,000 Devices in North America Alone, Demand is Already Exceeding Supply – Making INOL The Biotech Play of the Year!
INOL's revolutionary drug delivery device could transform a $9.8 Billion industry that is expected to hit $20 Billion by 2021.
Hi and good evening,
Tonight is pretty special, often is the case in the small markets that we find companies that are in the process of tapping into their potential but INOL is in rarified air. This will not be a long-winded report, tonight is too important for that, instead I'll stay on point with what you need to know before tomorrow morning. In a single paragraph I'll sum up INOL for you.
The amazing INOL story in one paragraph:
INOL's device is FDA Approved; in fact, it is the ONLY FDA approved over-the-counter needle-free injection device on the market today. Last year, in North America alone there was a shortage of 300,000 such needle-free devices. Instead of a traditional syringe with a needle, INOL's device injects medicine under the skin more efficiently and painlessly. It can be used to deliver "shots" for the treatment of Diabetes, Local Anesthesia, Vaccines & Growth Hormones as well as use in Dental, Veterinary and Aesthetic / Beauty practices. This summer INOL engaged investment banking firm Maxim Group LLC, a firm with $2.8 Billion under management, to assist INOL with funding so that INOL can help fill the 300,000 device shortage. As part of INOL's agreement with Maxim, Maxim will help INOL qualify and uplist to NASDAQ Capital Market. INOL's device is also approved by Health Canada (for use in Canada) and the European Medicines Agency (for use in Europe).
Now we can get into the details, but you already know the story… and it's an incredible one! So get INOL on your screen now and be ready tomorrow morning!
INOL has been called, "2017's Top Biotech Pick of the Year". See that very detailed report here: www.INOLReport.com
This is INOL's device, the Inojex30:
Here is the FDA's website showing you Inojex30's Product code, Device Class, Registration Number, Classification Name and that this is registered to the INOL as the owner:
INOL is anything but normal; don't let it pass you by. This could be a tremendously undervalued ground floor play. Get started on your research now and be ready for tomorrow morning.
Tonight's New Summer Blockbuster Play is Inolife Technologies, Inc. (INOL)
InoLife Technologies Inc. (INOL) develops and commercializes drug delivery devices, drug delivery technologies and products for the cure and care of our global customers. INOL's flagship product, the Inojex30, is an innovative needle-free technology that delivers a fine stream of medication subcutaneously without using a needle.
INOL's Inojex30 "fine stream of medication" is less than half the radius of a needle and delivers the medicine in a more efficient, uniform manner than traditional needles.
INOL recently engaged the services of investment bank Maxim Group to bring INOL and their technology to the next level.
At the time of INOL/Maxim's agreement, INOL President stated:
"This is a very important milestone for Inolife on our path to graduating to a national stock exchange," said Mr. Michael Wright, President & CEO of Inolife. "Maxim Group is a respected full-service investment banking firm with an impressive track-record of success in helping healthcare companies grow, and we are confident that they are the right corporate finance partner for Inolife."
INOL's biotechnology has a lot going for it right now:
Been approved by three top regulatory agencies, including the FDA
Manufactures only FDA approved over-the-counter needle-free injection device
Expecting to uplist to NASDAQ in 2018 following recent agreement with Maxim Group LLC
Those accomplishments and benchmarks are impressive enough yet what truly places INOL in an enviable position is growing demand inside the market they operate.
From 2012 to 2016 the injectable market has seen an increase of 43%
Injectable Drug Delivery Market worth 624.50 Billion USD by 2021
Currently, 16 Billion injections are received worldwide annually
Demand exceeds supply in North America, resulting in a shortage last year of 300,000 needle-free devices
As if this wasn't enough, the technology used by INOL is being backed by prominent organizations such as the World Health Organization, Centers for Disease Control and Prevention and various groups including the Bill and Melinda Gates Foundation.
Just what is this technology? Well it's an innovative needle-free technology that delivers a fine stream of medication subcutaneously without using a needle. The injections with the InoLife Inojex are virtually pain-free and do not lead to tissue damage on long term use. The InoLife injector is a reusable device, which utilizes disposable ampoules and other accessories.
We mentioned potential earlier and the opportunities that exist for this technology are vast. INOL lists a full menu of uses for their Inojex needle-free injector and these include:
Diabetes
Local Anesthesia
Dental
Vaccines & Growth Hormones
Veterinary
Aesthetic / Beauty
It's pretty easy to understand why we are excited about INOL. The regulatory approval alone is enough to take notice, as is the market size and expected growth, so too are the many uses of this technology. Now understand that we have all three of these together in one company.
Simply put, INOL should absolutely be on the top of your trading screen tomorrow!
Like I said, tonight's play is pretty rare and pretty special. It's not often you see a company with a technology this advanced and FDA approved on the small markets.
I make no attempt to hide our love for biotech. There are few things in the small markets more beautiful and more exciting than a biotech that catches fire.
When investors find a new biotech that they can get behind it can skyrocket!
INOL could be that next biotech to capture the imagination of the small market and light it up!
Also, today INOL slid all the way down to .15, although the bid and offer has already started to rise back up.
Yesterday INOL closed at .30 and it was trading up over $2 this summer!
Today's slide could have opened a very big door.
Not only does INOL have operations that could place its value well above its current level, it could also see a significant bounce right around the corner.
A return to where it was this morning could translate to a 100% run.
A return to its summer levels could translate to a colossal run of 1,233%.
It's not often that we see situations like this; this play could be epically undervalued!
Now to be clear no one is expecting it to see a return to those summer levels in the short term, but even a fraction could translate to a massive percentage!
Like I said at the start, tonight's play is something quite special.
Have INOL on the top of your screen tomorrow morning.
Situations like this do not come along every day. We urge members to take Swift Action and start your research right away. We could be looking at something Exceptional!
As always, we encourage you to do further research.
New Trade Alert: OncoSec Medical Incorporated (NASDAQ: ONCS)
A Little About ONCS:
“OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12.
In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response.
ImmunoPulse® IL-12, OncoSec’s lead program, is currently in clinical development for metastatic melanoma and triple-negative breast cancer.
The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies.
In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform.”
Latest Headline:
ONCS released breaking news this morning that may provide an additional catalyst for upside potential.
OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors
Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems adds significant biopharma clinical, regulatory, business development, and fundraising expertise to OncoSec
SAN DIEGO, Sept. 7, 2017 /PRNewswire/ — OncoSec Medical Incorporated “OncoSec” (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O’Connor to its Board of Directors. Mr. O’Connor brings more than 20 years of successful financing and licensing experience to OncoSec’s Board of Directors, most recently serving as President and Chief Executive Officer of Advaxis Immunotherapies. His appointment to the Company’s Board is effective immediately.
“Dan is a proven leader with a strong track record of success. He brings exceptional strategic and operational expertise in building thriving, successful biopharma companies, and we are pleased to welcome Dan to the Board,” said Punit Dhillon, President and CEO of OncoSec. “His history with commercializing and licensing cancer immunotherapy products will be vital as we continue to progress our lead melanoma program through clinical trials and registration.”
“OncoSec’s ImmunoPulse® IL-12 clinical program in melanoma and broader pipeline have the potential to address significant unmet needs for cancer patients with few or no treatment options,” said Mr. O’Connor. “I am excited about the potential therapeutic opportunity to combine with and enhance the existing success of the checkpoint inhibitor class of compounds. I believe that OncoSec has the leading platform to address late stage relapsed or refractory solid tumors and look forward to contributing to the advancement of the Company’s exciting portfolio.”
Most recently, as President and Chief Executive Officer of Advaxis Immunotherapies, Mr. O’Connor successfully turned around the company, raising more than $250 million in funding and transforming it into a patient-focused, leading cancer immunotherapy company. He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda® and Opdivo®. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research. Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.
OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be presenting at several events in September, including:
Rodman & Renshaw 18thAnnual Global Investment Conference
Johnson & Johnson Innovation + JLABS Science 1stSpeaking Series
Phacilitate Cell & Gene Therapy Europe 2017
2ndWorld Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Rodman & Renshaw 18th Annual Global Investment Conference Punit Dhillon, OncoSec’s Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference on September 11th at 10:25 AM ET at The Lotte New York Palace Hotel in New York City.
OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors
Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company” (ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec’s Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Her election to the Company’s Board is effective immediately.
“We are very pleased to have Dr. Jenkins join our Board as we believe her international biopharma drug development experience will be an asset to OncoSec as we advance our lead melanoma program and pursue collaborations with other industry leaders in oncology,” said Punit Dhillon, President and CEO of OncoSec. “Drawing on her years of experience in the biopharma industry, we believe Dr. Jenkins will provide new insights to our technology and business priorities as we continue to advance our broad clinical portfolio and achieve future growth objectives.”
“I believe OncoSec’s clinical program for ImmunoPulse® IL-12 can have a significant impact on how we approach cancer care by addressing a significant unmet need for melanoma patients that do not currently respond to anti-PD-1 treatments. In addition, I’m impressed with the Company’s commitment to advancing its innovative drug development approach, putting science and patients at the core of its mission,” said Dr. Jenkins. “I look forward to contributing to the Company’s advancement of its promising product candidates through clinical development.”
Prior to Dimension Therapeutics, Dr. Jenkins served as Executive Vice President and Head of Global Research and Development for Merck Serono, a global division of Merck KGaA focused on biopharmaceuticals. She also led Global Medical Affairs and Quality at Merck Serono and was a member of its Pharmaceutical Executive Committee. Dr. Jenkins also had a nearly 15-year career at Bristol-Myers Squibb, attaining the role of Senior Vice President and Head of Global Medical Affairs. She began her career as a Medical Officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins received an MBBS in Medicine from St. Bartholomew’s Hospital in the University of London and trained in cardiovascular medicine in the National Health Service (U.K.).
Currently, Dr. Jenkins serves as a director for several companies including: Ardelyx, Inc., Biothera Pharmaceutical Inc., iOX Therapeutics Limited, MedCity and Vium. She also is a committee member of the Science Board to the U.S. Food and Drug Administration, serves on the Board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association.
We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
Sincerely,
AST Team
Disclaimer: We have received five thousand dollars via a bank wire for the awareness of ONCS.
Any type of reproduction, copying or distribution of the material in this email is prohibited without a written consent from the site owner.
All of the information in this blog is gathered from public information released by the company. By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.
“US Lithium Corp. announces it has entered into a Letter Of Intent
The story really started with the acquisition of Vitel Laboratorios, S.A. de C.V, which got the
As if this wasn't enough, the technology used by INOL is being backed by prominent organizations such as the World Health Organization, Centers for Disease Control and Prevention and various groups including the Bill and Melinda Gates Foundation.
a company with a technology this advanced and FDA approved on the small markets.
A return to its summer levels could translate to a colossal run of 1,233%.